title: Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas.
abstract: Non-small cell lung cancers (NSCLCs) have molecular characterization and most druggable genetic and molecular abnormalities, such as EGFR, ERBB2 and BRAF mutations, and ALK and ROS1 rearrangements, have been observed in a subset of adenocarcinomas or large cell carcinomas [1]. Even if these abnormalities are seldom detected in squamous cell carcinomas (SQCC), some rare cases of SQCC have been reported to harbor EGFR, ROS1 or ALK genetic alterations with in some cases a response to targeted therapies [2,3]. Here, we describe a patient with a SQCC harboring ROS1 rearrangement and a response to the target therapy, crizotinib.
authors.affiliation: Resident of Pneumology, University of Lyon, France. Electronic address: gibelin.cecilia@outlook.fr.
authors.forename: Cécilia
authors.initials: C
authors.lastname: Gibelin
authors.affiliation: Clinical Oncology, Cancer Center « Centre Léon Bérard » Lyon, University of Lyon, France.
authors.forename: Virginie
authors.initials: V
authors.lastname: Avrillon
authors.affiliation: Department of Biopathology, Cancer center « Centre Léon Bérard » Lyon, University of Lyon, France.
authors.forename: Arnaud
authors.initials: A
authors.lastname: De La Fouchardiere
authors.affiliation: Molecular Genetics Platform, Department of Pathology, CHU Grenoble, University of Grenoble Alpes, Institute A. Bonniot INSERM U 823 La Tronche, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Mc Leer-Florin
authors.affiliation: Department of Biopathology, Cancer center « Centre Léon Bérard » Lyon, University of Lyon, France,; University of Grenoble Alpes, Institute A. Bonniot INSERM U 823 La Tronche, France.
authors.forename: Sylvie
authors.initials: S
authors.lastname: Lantuejoul
authors.affiliation: Clinical Oncology, Cancer Center « Centre Léon Bérard » Lyon, University of Lyon, France.
authors.forename: Jérôme
authors.initials: J
authors.lastname: Fayette
mesh_terms: D000328:Adult; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000235:genetics*; D000077547:Crizotinib; D005260:Female; D015321:Gene Rearrangement; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000235:genetics; D009154:Mutation; D000072078:Positron Emission Tomography Computed Tomography; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000235:genetics* / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000235:genetics* / Q000378:metabolism; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D047428:Protein Kinase Inhibitors; D011518:Proto-Oncogene Proteins; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; D011505:Protein-Tyrosine Kinases; C062333:ROS1 protein, human
keywords: Crizotinib; Lung cancer; Non-smoker; Partial response; ROS1 rearrangement; Squamous cell carcinoma